Seres Therapeutics Inc MCRB

Healthcare Biotechnology

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

NDAQ:MCRB - Post by User

Seres Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(102)
•••

Post by Napcooon Mar 28, 2024 11:26pm

189 Views

Post# 35959693

Now it's time to accumulate @78 cents

$225 mln due if target milestone reached for the $575 mln deal, $175 mln upfront, $125 mln FDA approved, latest updates to reach sales target in 2024, which 2024 financial year? https://www.pharmaceutical-technology.com/news/seres-nestle-microbiome-therapeutic/?cf-view

<< Previous

Bullboard Posts

Next >>

NEO Battery Materials: Making companies like Rheinmetall and Mercedes-Benz less dependent on China's battery market